Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate

Contraception

Volumn 79, Issue 4, 2009, Pages 282-289

  Palombo Kinne, Ernesta ^a   Schellschmidt, Ilka ^a   Schumacher, Ulrike ^a   Gräser, Thomas ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Acne; Cyproterone acetate; Diane 35; Dienogest; Oral contraceptives; Randomized clinical trial; Skin; Valette

Indexed keywords

CYPROTERONE ACETATE; DIANE; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ACNE; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALLSTONE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASTALGIA; METRORRHAGIA; MULTICENTER STUDY; NAUSEA; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEBUM SECRETION; SIDE EFFECT; STROKE; TABLET FORMULATION; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ACNE VULGARIS; ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; CYPROTERONE ACETATE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NANDROLONE; YOUNG ADULT;

EID: 61449125810     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.10.010     Document Type: Article

References (20)

1. Thiboutot D.M. Overview of acne and its treatment. Cutis 81 Suppl 1 (2008) 3-7
2. Webster G.F. Acne vulgaris. State of the science. Arch Dermatol 135 (1999) 1101-1102
3. Mercurio M.G., and Gogstetter D.S. Androgen physiology and the cutaneous pilosebaceous unit. J Gend Specif Med 3 (2000) 59-63
4. Beylot C., Doutre M.S., and Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 196 (1998) 148-152
5. Tan J.K., and Degreef H. Oral contraceptives in the treatment of acne. Skin Therapy Lett 6 (2001) 1-3
6. O'Connell K., and Westhoff C. Pharmacology of hormonal contraceptives and acne. Cutis 81 Suppl 1 (2008) 8-12
7. Schindler A.E. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur J Obstet Gynecol Reprod Biol 112 (2004) 136-141
8. Sitruk-Ware R. New progestogens for contraceptive use. Hum Reprod Update 12 (2006) 169-178
9. Oettel M., Carol W., Elger W., et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today (Barc) 31 (1995) 517-536
10. Oettel M., Gräser T., Hoffmann H., Moore C., Zimmermann H., and Zimmermann T. The preclinical and clinical profile of dienogest: a short overview. In: Nikolov R., Hoffmann H., and Oettel M. (Eds). Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc) 35(Suppl C) (1999) 3-12
11. Pochi P.E., Shalita A.R., Strauss J.S., et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24-25, 1990. J Am Acad Dermatol 24 (1991) 495-500
12. Barbier N., Paul C., Luger T., et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 150 (2004) 96-102
13. EMEA/CPMP/EWP/2158/99: Concept paper on the development of a Committee for Proprietary Medicinal Products (CPMP): points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. London, 1999.
14. EMEA/CPMP/EWP/2158/99: Committee for Proprietary Medicinal Products (CPMP): guideline on the choice of the non-inferiority margin. London, 27 July 2005.
15. ® on skin and hair: a post-marketing surveillance study. Int J Clin Pract 54 (2000) 85-91
16. ®. In: Nikolov R., Hoffmann H., and Oettel M. (Eds). Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc) 35(Suppl C) (1999) 69-78
17. Huber J., and Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 73 (2006) 23-29
18. Golbs S., Klinger G., Moore C., Walter F., and Mellinger U. Beeinflussung klinisch-chemischer und hämatologischer Parameter nach Verabreichung von MP 2000 über 6 Zyklen an gesunden Probandinnen im Rahmen einer Pilot-Studie. In: Teichmann A.T. (Ed). Dienogest. Präklinik und Klinik eines Gestagens. 2nd ed. (1995), Walter de Gruyter, Berlin 191-201
19. Wiegratz I., Lee J.H., Kutschera E., et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 65 (2002) 223-229
20. ®. In: Nikolov R., Hoffmann H., and Oettel M. (Eds). Dienogest. A clinical study update on dienogest-containing products. Drugs Today (Barc) 35 (Suppl C) (1999) 53-68